179250-28-3

Usage

Uses

Used in Pharmaceutical Research:
TERT-BUTYL 4-[2-(HYDROXYMETHYL)PHENYL]TETRAHYDRO-1(2H)-PYRAZINECARBOXYLATE is used as a pharmaceutical intermediate for its potential to contribute to the development of new drugs and biologically active molecules. Its unique structure and reactivity allow for the creation of diverse therapeutic agents.
Used in Organic Synthesis:
In the field of organic synthesis, TERT-BUTYL 4-[2-(HYDROXYMETHYL)PHENYL]TETRAHYDRO-1(2H)-PYRAZINECARBOXYLATE serves as a key component in the synthesis of complex organic molecules. Its ability to react with various other compounds makes it instrumental in the production of specialty chemicals and materials.
Used in Therapeutic Applications:
TERT-BUTYL 4-[2-(HYDROXYMETHYL)PHENYL]TETRAHYDRO-1(2H)-PYRAZINECARBOXYLATE is used as a precursor in the formulation of therapeutic agents, given its potential pharmacological properties. It is being explored for its role in various medicinal applications, highlighting its importance in advancing healthcare solutions.

InChI:InChI=1/C16H24N2O3/c1-16(2,3)21-15(20)18-10-8-17(9-11-18)14-7-5-4-6-13(14)12-19/h4-7,19H,8-12H2,1-3H3

Upstream product

• 174855-57-3 tert-butyl 4-(2-formylphenyl)piperazinecarboxylate 
• 446-52-6 2-Fluorobenzaldehyde 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 111373-03-6 2-(piperazin-1-yl)benzonitrile 
• 24424-99-5 di-tert-butyl dicarbonate 
• 444582-90-5 2-{4-[(tert-butoxy)carbonyl]piperazin-1-yl}benzoic acid 
• 446831-27-2 2-(piperazin-1-yl)benzoic acid 

Downstream Products

• 209160-88-3 1-t-butoxycarbonyl-4-(2-(methanesulfonyloxymethyl)phenyl)-piperazine 
• 179250-29-4 1-tert-butoxycarbonyl-4-(2-(imidazol-1-ylmethyl)phenyl)piperazine 
• 923297-65-8 4-(2-methoxymethyl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester 
• 321909-01-7 [2-(piperazin-1-yl)phenyl]methanol 
• 1314044-12-6 1-[2-(3-iodophenoxymethyl)phenyl]piperazine mono-trifluoroacetate 
• 1201927-58-3 C₁₇H₂₀N₂O 
• 1201927-96-9 C₁₆H₂₃ClN₂O₂ 
• 1201927-62-9 C₁₇H₁₈F₂N₂O 
• 1201927-64-1 C₂₀H₂₄N₂O 
• 1201927-60-7 C₁₇H₁₉FN₂O 
• 174855-59-5 1-t-Butoxycarbonyl-4-(2-(1'-(1',2',4'-triazolyl)methyl)phenyl)-piperazine 
• 179250-42-1 4-(2-[1,2,4]triazol-4-ylmethyl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester 
• 209160-87-2 1-(2-(1'-(1',2',4'-triazolyl)-methyl)phenyl)-piperazine 
• 444582-00-7 1-tert-butoxycarbonyl-4-[2-((2-methylimidazol-1-yl)methyl)phenyl]piperazine 

Relevant academic research and scientific papers

(2-benzylphenyl)piperazine derivatives and use thereof

The invention discloses (2-benzylphenyl)piperazine derivatives, a use thereof, and a medicinal composition comprising above compounds. The derivatives and the medicinal composition are used for inhibiting serotonin reuptake. The invention also relates to

1-(2-PHENOXYMETHYLPHENYL)PIPERAZINE COMPOUNDS

The invention relates to compounds of formula I: where a, and R1 through R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhi

Structure-activity relationship studies on a series of piperazinebenzylalcohols and their ketone and amine analogs as melanocortin-4 receptor ligands

A series of piperazinebenzylalcohols were prepared and studied to compare with their ketone and amine analogs as MC4R antagonists. Several benzylalcohols such as 14a and 14g displayed low nanomolar binding affinities (Ki 10 nM), and high sele

Synthesis and Structure-Activity Relationships of Novel Arylpiperazines as Potent and Selective Agonists of the Melanocortin Subtype-4 Receptor

The melanocortin receptors have been implicated as potential targets for a number of important therapeutic indications, including inflammation, sexual dysfunction, and obesity. We identified compound 1, an arylpiperazine attached to the dipeptide H-D-Tic-D-p-Cl-Phe-OH, as a novel melanocortin subtype-4 receptor (MC4R) agonist through iterative directed screening of nonpeptidyl G-protein-coupled receptor biased libraries. Structure-activity relationship (SAR) studies demonstrated that substitutions at the ortho position of the aryl ring improved binding and functional potency. For example, the o-isopropyl-substituted compound 29 (Ki = 720 nM) possessed 9-fold better binding affinity compared to the unsubstituted aryl ring (Ki = 6600 nM). Sulfonamide 39 (Ki = 220 nM) fills this space with a polar substituent, resulting in a further 2-fold improvement in binding affinity. The most potent compounds such as the diethylamine 44 (Ki = 60 nM) contain a basic group at this position. Basic heterocycles such as the imidazole 50 (Ki = 110 nM) were similarly effective. We also demonstrated good oral bioavailability for sulfonamide 39.

Aryl piperazine melanocortin MC4 receptor agonists

Incorporation of substituted phenyl piperazine privileged structures into a known MC4 specific dipeptoid consensus sequence resulted in a series of potent (EC50=24 nM) and selective MC4-R agonists. We report the SAR of this series of compounds

Substituted aryl piperazines as neurokinin antagonists

Disclosed are substituted aryl piperazines of Formula I STR1 are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis. In particular compounds of Formula I are shown to be neurokinin antagonists.